Navigation Links
Sales of Etimicin Sulfate to Expand Nationwide as Government Restriction is Lifted
Date:10/9/2007

SANTA MONICA, Calif., Oct. 9 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA), one of mainland China's leading pharmaceutical companies, today announced that the Chinese government has loosened national restrictions for the sale of Etimicin sulfate throughout China. Aida expects the sales of the Company's main revenue-generating product to increase noticeably as sales efforts are pursued nationwide without restriction.

The Ministry of Labor and Social Security eliminated restrictions on Etimicin, which is in the aminoglycoside antibiotic family. Aminoglycoside antibiotis were previously thought to be potentially unsafe for treating patients with a history of kidney disease. Although Etimicin had been clinically established to be safe and effective for people with such issues, it was not until now that the restrictions have been lifted.

Jin Biao, Chairman and CEO of Aida Pharmaceuticals, noted, "This is strong substantiation by the appropriate governmental regulatory body that the safeness of Etimicin has been universally and officially recognized. We are definitely pleased at this acceptance of the outstanding characteristic of low toxicity in this new generation of aminoglycoside antibiotics. We believe that this will allow us to promote the sales of Etimicin and broaden our customer base."

For more information about the lifting of the restriction for this particular type of drug please visit: http://www.molss.gov.cn/gb/ywzn/2007-06/20/content_183083.htm

About Etimicin Sulfate

Etimicin Sulfate is a new generation of the aminoglycoside family of antibiotics. Developed by Aida and its research partners, it is the first antibiotic developed in China. Aida has the exclusive right to the production and marketing of this powder and infusion type and is protected by patent through 2013. Etimicin sulfate is a semi-synthesized soluble antibiotic.

Researchers and doctors who performed the clinical tests believe that the product is a new generation of aminoglycoside antibiotics with high efficiency, safety and effectiveness to a broad spectrum of strains. Etimicin sulfate is suitable for the treatment of various inflammations, such as respiratory infections, kidney and urinogenital infections, soft skin tissue infection, as well as trauma and operation preventative uses.

About Aida

Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices.


'/>"/>
SOURCE Aida Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Jellyfish partners for sales tracking technology
2. Doyle wants sales tax applied to digital downloads
3. Mortgagebot builds online sales even as housing declines
4. Third Wave reports another loss, stronger sales
5. Johnson Controls reports record quarterly sales
6. Can sales outsourcing grow Wisconsin biotechs?
7. Sonic Foundry reports quarterly loss, higher Mediasite sales
8. My-oh, its BIO! Where sales hype and science collide
9. Third Wave shuffles finance, sales management
10. Johnson Controls sales up, profits down
11. Turning ads into sales: Context is king
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
Breaking Biology News(10 mins):